Platelet derived growth factor induced tenascin-C transcription is phosphoinositide 3-kinase/Akt-dependent and mediated by Ets family transcription factors

Journal of Cellular Physiology

Volumn 206, Issue 3, 2006, Pages 718-727

  Jinnin, Masatoshi ^a   Ihn, Hironobu ^a   Asano, Yoshihide ^a   Yamane, Kenichi ^a   Trojanowska, Maria ^b   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLOHEXIMIDE; CYTOKINE; DACTINOMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN SYNTHESIS INHIBITOR; TENASCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR FLI1; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; BINDING SITE; CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; FIBROBLAST; GENE; GENE CONTROL; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TN C GENE; TRANSCRIPTION REGULATION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASE SEQUENCE; DERMIS; FEMALE; FIBROBLASTS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; PLATELET-DERIVED GROWTH FACTOR; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-ETS; RESPONSE ELEMENTS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TENASCIN; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 31944443343     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20527     Document Type: Article

References (50)

1. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541-6551.
2. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. 1997. Role of translocation in the activation and function of protein kinase B. Biol Chem 272:31515-31524.
3. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, Thomas G, Ghysdael J. 1994. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14:3230-3241.
4. Bentley D, Groudine M. 1986. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 321:702-706.
5. Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L. 1994. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun 1:307-317.
6. Celano P, Berchthold C, Casero RA, Jr. 1989. A simplification of the nuclear run-off transcription assay. BioTechniques 7:942-944.
7. Chiquet M, Wehrle-Haller B. 1994. Tenascin-C in peripheral nerve morphogenesis. Dev Neurobiol 2:67-74.
8. Chiquet M, Sarasa-Renedo A, Tunc-Civelek V. 2004. Induction of tenascin-C by cyclic tensile strain versus growth factors: Distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta 1693:193-204.
9. Cohen MA, Eaglstein WH. 2001. Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermatol 45:857-862.
10. Crossin KL. 1996. Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease. J Cell Biochem 61:592-598.
11. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. 2001. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276:20839-20848.
12. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. 2002. Etsl is an effector of the transforming growth factor b (TGF-b) signaling pathway and an antagonist of the profibrotic effects of TGF-b. J Biol Chem 277:20399-20408.
13. Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, Dietze O, Wirl G. 2001. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: Correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 193:181-189.
14. Ekblom P, Aufderheide E. 1989. Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions. Int J Dev Biol 33:71-79.
15. Erickson HP. 1993. Tenascin-C, tenascin-R and tenascin-X: A family of talented proteins in search of functions. Curr Opin Cell Biol 5:869-876.
16. Fu M, Zhu X, Wang Q, Zhang J, Song Q, Zheng H, Ogawa W, Du J, Chen YE. 2001. Platelet-derived growth factor promotes the expression of peroxisome proliferator-activated receptor g in vascular smooth muscle cells by a phosphatidylinositol 3-kinase/Akt signaling pathway. Circ Res 89:1058-1064.
17. Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L. 1995. Human tenascin gene. Structure of the 5′-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem 270:3429-3434.
18. Gulcher JR, Nies DE, Marton LS, Stefansson K. 1989. An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites. Proc Natl Acad Sci USA 86:1588-1592.
19. Hagen G, Muller S, Beato M, Suske G. 1994. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 13:3843-3851.
20. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ, Bowen-Pope DF. 1988. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240:1529-1531.
21. Heldin CH, Westermark B. 1990. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul 1:555-566.
22. Heldin CH, Johnsson A, Wennergren S, Wernstedt C, Betsholtz C, Westermark B. 1986. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature 319:511-514.
23. Heldin CH, Backstrom G, Ostman A, Hammacher A, Ronnstrand L, Rubin K, Nister M, Westermark B. 1988. Binding of different dimeric forms of PDGF to human fibroblasts: Evidence for two separate receptor types. EMBO J 7:1387-1393.
24. Heldin CH, Ostman A, Ronnstrand L. 1998. Signal transduction via platelet-derived growth factor receptors. Biochem Biophys Acta 1378:F79-F113.
25. Higaki M, Sakaue H, Ogawa W, Kasuga M, Shimokado K. 1996. Phosphatidylinositol 3-kinase-independent signal transduction pathway for platelet-derived growth factor-induced chemotaxis. J Biol Chem 271:29342-29346.
26. Ihn H, Tamaki K. 2000. Competition analysis of the human a2(I) collagen promoter using synthetic oligonucleotides. J Invest Dermatol 114:1011-1016.
27. Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M. 1996. Transcriptional regulation of the human a2(I) collagen gene. Combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem 271:26717-26723.
28. Ihn H, LeRoy EC, Trojanowska M. 1997. Oncostatin M stimulates transcription of the human a2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 272:24666-24672.
29. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. 2002. IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway. J Immunol 168:1895-1902.
30. Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. 2004. Tenascin-C upregulation by transforming growth factor-b in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene 23:1656-1667.
31. Klinghoffer RA, Hamilton TG, Hoch R, Soriano P. 2002. An allelic series at the PDGFaR locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell 2:103-113.
32. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. 1990. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 170:56-60.
33. Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S, Kusakabe M. 1998. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol 111:930-935.
34. Mackie EJ. 1997. Molecules in focus: Tenascin-C. Int J Biochem Cell Biol 29:1133-1137.
35. Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. 1996. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 107:856-859.
36. McCachren SS, Lightner VA. 1992. Expression of human tenascin in synovitis and its regulation by interleukin-1. Arthritis Rheum 35:1185-1196.
37. Merscher S, Hanselmann R, Welter C, Dooley S. 1994. Nuclear runoff transcription analysis using chemiluminescent detection. Biotechniques 16:1024-1026.
38. Murakami R, Yamaoka I, Sakakura T. 1989. Appearance of tenascin in healing skin of the mouse: Possible involvement in seaming of wounded tissues. Int J Dev Biol 33:439-444.
39. Natali PG, Nicotra ME, Bigotti A, Botti C, Castellani P, Risso AM, Zardi L. 1991. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer 47:811-816.
40. Rettig WJ, Garin-Chesa P. 1989. Cell type-specific control of human neuronectin secretion by polypeptide mediators and phorbol ester. J Histochem Cytochem 37:1777-1786.
41. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. 1989. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem 264:8771-8778.
42. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK. 1998. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 17:2883-2888.
43. Sharifi BG, LaFleur DW, Pirola CJ, Forrester JS, Fagin JA. 1992. Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 267:23910-23915.
44. Shirasaki F, Makhluf HA, LeRoy C, Watson DK, Trojanowska M. 1999. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 18:7755-7764.
45. Singer AJ, Clark RA. 1999. Cutaneous wound healing. N Engl J Med 341:738-746.
46. Stroopbant P, Waterfield MD. 1984. Purification and properties of porcine platelet-derived growth factor. EMBO J 3:2963-2967.
47. Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. 1993. Tenascin expression in the mouse: In situ localization and induction in vitro by bFGF. J Cell Sci 104:69-76.
48. Tymms MJ, Kola I. 1994. Regulation of gene expression by transcription factors Ets-1 and Ets-2. Mol Reprod Dev 39:208-214.
49. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, Miyazono K, Kato M. 2002. c-myc is a downstream target of the Smad pathway. J Biol Chem 277:854-861.
50. Yamane K, Ihn H, Tamaki K. 2003. Epidermal growth factor up-regulates expression of transforming growth factor b receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 48:1652-1666.